ข่าวประชาสัมพันธ์ Metastatic Breast Cancer+the European Union
Menarini Group's Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced or Metastatic Breast Cancer
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union Submission supported by results from the pivotal Phase 3 EMERALD study showing a statistically significant difference in the efficacy in favor of elacestrant over current standard-of-care (SOC) medications for both the overall study population and patients
LIV-24 applies ESG Tech AI technology, revolutionising industrial sector Cuts costs, increases productivity, facilitates sustainable business
—
At present,...
TAT and International Partners Urge Thai Businesses to Prepare for Imminent EU Regulations on Sustainable Tourism
—
On September 26, at the Avani+ Riversi...
Menarini Group Presented Initial Safety and Efficacy Data from Phase 1b/2 ELEVATE and ELECTRA Combination Studies of ORSERDU(R) (Elacestrant) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium
ELEVATE and ELECTRA studies were designed with the ob...Menarini Group Presents New Progression-Free Survival Data from EMERALD Clinical Study of ORSERDU(R) (Elacestrant) in Clinically Relevant Subgroups of Patients with ER+, HER2- Metastatic Breast Cancer (mBC) with ESR1 Mutations at SABCS 2023
This new post hoc analysis of the Phase 3 EMERALD trial evalu...
International efforts to protect and empower ASEAN's women migrant workers
—
International organisations under the United Nations (UN) and the European Un...
Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU(R) (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer
ORSERDU is the first treatment specifically approved for patients with ER+, HER2- advanced or metas...Artmarket.com: France obtains the maintenance of VAT at the reduced rate of 5.5% on the Art Market, a major victory with very considerable advantages according to Artprice.
France's art market professionals will be extremely relieved by this news. The French government has decided to maintain the VAT...European Commission Approves Menarini Group's ORSERDU(R) (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation
Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen...TerraPay Group Expands Business Operations in Italy and Sets Sights on European Union
TerraPay, a leading global payments infrastructure company, today announced that it has secured authorization as an Electronic Money Institute (EMI) in Italy. Having obtained approval from the Bank of Italy,...Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU(R) (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation
Each year in Europe more than 550,000 patients are diagnosed with breast cancer...
EXPORT PROMOTION SEMINAR TO HIGHLIGHT EXCELLENCE OF EUROPEAN FOOD
—
H.E. Mr. David Daly, Ambassador of the European Union to Thai (EU) is set to host a tw...
Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU(R) (Elacestrant) in Metastatic Breast Cancer at ASCO 2023
ORSERDU (elacestrant) was approved by the FDA in January 2023 for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or...Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
ESR1 mutations are present in up to 40% of ER+, HER2-...CGTN: China, EU aim to strengthen ties in the face of global challenges
China and the European Union (EU) on Thursday called for further developing their comprehensive strategic partnership as the world faces various challenges. "The more unstable the international situation becomes and the more...New Pesticide Usage Norms to Impact Agri-Export from Developing Countries - CENTEGRO
A well-guided effort is underway to seek the revocation of the inconsistent trade measures imposed by WTO at the next meeting of the World Trade Organisation Sanitary and Phytosanitary Committee (7th - 11th November...Menarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from 2L and 3L ER+/HER2- advanced...Xinhua Silk Road: Seraphim, Resolar sign MoU to deepen cooperation in EU market amid REPowerEU plan
Seraphim Energy Group Co., Ltd. (Seraphim), a leading global solar product manufacturer, signed a memorandum of understanding (MoU) with Resolar, a Luxembourg-based energy company in early July, with...Novavax Nuvaxovid(TM) COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17
Nuvaxovid(TM) COVID-19 vaccine is the first protein-based option for adolescents aged 12 through 17 in Europe Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to...Novavax COVID-19 Vaccine Nuvaxovid(TM) Recommended for Expanded Conditional Marketing Authorization in the European Union by CHMP for Adolescents Aged 12 Through 17
Upon authorization, Nuvaxovid(TM) would be the first protein-based option for adolescents aged 12 through 17 in Europe Nuvaxovid(TM)...Trinohex(R) Ultra LIB electrolyte additive now available in EU
Ascend Performance Materials' Trinohex(R) Ultra is now REACH-registered and available across the European Union. "The demand for safe, reliable and longer-lasting batteries will only increase as we continue to shift toward e-mobility and...Menarini Progresses Into the Clinic With MEN1611, a PI3K Inhibitor for the Treatment of HER2 Positive Metastatic Breast Cancer
Menarini Ricerche announced today the initiation of the B-PRECISE-01 clinical trial, a multicenter phase Ib study that will evaluate the safety and efficacy of MEN1611 plus...
ภาพข่าว: เครือข่ายมะเร็งเต้านมภาคเหนือตอนบน จัดอบรม “การตรวจคัดกรองและดูแลผู้ป่วยมะเร็งเต้านมระยะแพร่กระจาย”
—
รศ.พญ. อิ่มใจ ชิตาพนารักษ์ หน่วยรังสีรักษาแ...